RT Journal Article
SR Electronic
T1 Synergistic Role of NK Cells and Monocytes in Promoting Atherogenesis in Severe COVID-19 Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.10.23298322
DO 10.1101/2023.11.10.23298322
A1 Gunasena, Manuja
A1 Alles, Mario
A1 Wijewantha, Yasasvi
A1 Mulhern, Will
A1 Bowman, Emily
A1 Gabriel, Janelle
A1 Kettelhut, Aaren
A1 Kumar, Amrendra
A1 Weragalaarachchi, Krishanthi
A1 Kasturiratna, Dhanuja
A1 Horowitz, Jeffrey C
A1 Scrape, Scott
A1 Pannu, Sonal R
A1 Liu, Shan-Lu
A1 Vilgelm, Anna
A1 Wijeratne, Saranga
A1 Bednash, Joseph S
A1 Demberg, Thorsten
A1 Funderburg, Nicholas T
A1 Liyanage, Namal P.M.
YR 2023
UL http://medrxiv.org/content/early/2023/11/12/2023.11.10.23298322.abstract
AB Clinical data demonstrate an increased predisposition to cardiovascular disease (CVD) following severe COVID-19 infection. This may be driven by a dysregulated immune response associated with severe disease. Monocytes and vascular tissue resident macrophages play a critical role in atherosclerosis, the main pathology leading to ischemic CVD. Natural killer (NK) cells are a heterogenous group of cells that are critical during viral pathogenesis and are known to be dysregulated during severe COVID-19 infection. Their role in atherosclerotic cardiovascular disease has recently been described. However, the contribution of their altered phenotypes to atherogenesis following severe COVID-19 infection is unknown. We demonstrate for the first time that during and after severe COVID-19, circulating proinflammatory monocytes and activated NK cells act synergistically to increase uptake of oxidized low-density lipoprotein (Ox-LDL) into vascular tissue with subsequent foam cell generation leading to atherogenesis despite recovery from acute infection. Our data provide new insights, revealing the roles of monocytes/macrophages, and NK cells in COVID-19-related atherogenesis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partially supported by National Center for Advancing Translational Sciences (KL2TR002734 and UL1TR002733 to [J.S.B.]).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We obtained approval from the Research Ethics Committee in The Ohio State University under the following IRB protocols (2020H0175, 2020H0228, 2014H0467, 2020H0339), and all patients gave informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes